Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)
Novo Nordisk faces growth deceleration concerns, intensified by competitive pressures from Eli Lilly and supply chain issues. NVO can improve buying sentiments by expanding its indications beyond its core weight loss and diabetes categories. NVO's growth-adjusted valuation has improved markedly, while its first-mover advantage should anchor its ability to scale profitably.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
Ozempic, weight loss drugs found to cut substance abuse
Weight loss drugs such as Novo Nordisk (NYSE:NVO) AS' Ozempic have been found to cut alcohol and opioid abuse, according to a new study. Published in the journal Addiction, the study showed the rate of opioid overdoses among people taking GLP-1 drugs was 40% lower than those who were not.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Wegovy weight loss drug roll out falling short in the UK
Plans to roll out weight loss drug Wegovy through the NHS have fallen short of expectations after the treatment's approval late last year. Just 800 patients had received prescriptions of the drug by April, according to Sky News, against Department of Health estimates that 13,500 people would be on Wegovy by then.
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups, a top executive told Reuters.
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk (NVO) closed the most recent trading day at $117.20, moving -0.48% from the previous trading session.
Novo Nordisk downgraded amid supply bottlenecks
Jefferies has downgraded its rating on Novo Nordisk (NYSE:NVO) to "underperform" and cut its price target to DKK 575, down from the previous DKK 782.90. The downgrade comes amid concerns over the supply of the Danish drugs giant's weight-loss drug, Wegovy, particularly in the United States, where prescriptions for the 0.25 mg starter dose have dropped significantly.
Novo Nordisk to invest $158 million in insulin plant in Brazil
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production globally, the firm said on Friday.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem.
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter.
